Cipla reported INR70.14B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Arca Biopharma USD 22.97M 6.34M Jun/2026
aTyr Pharma USD 11.4M 303K Jun/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 12.38M 621K Jun/2026
Capricor Therapeutics USD 32.96M 676K Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
Dr.Reddys Laboratories INR 157.34B 10.13B Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sun Pharmaceuticals INR 226.22B 7.93B Mar/2026
TherapeuticsMD USD 5.82M 655K Jun/2024
UPL INR 347.48B 16.58B Mar/2026